The challenges in moving from ageing to successful longevity

Genovefa Kolovou, Nir Barzilai, Calogero Caruso, Ewa Sikora, Miriam Capri, Irene P. Tzanetakou, Helen Bilianou, Peter Avery, Niki Katsiki, George Panotopoulos, Claudio Franceschi, Athanase Benetos, Dimitri P. Mikhailidis

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

During the last decades survival has significantly improved and centenarians are becoming a fast-growing group of the population. Human life span is mainly dependent on environmental and genetic factors. Favourable modifications of lifestyle factors (e.g. physical activity, diet and not smoking) and healthcare (e.g. effective vascular disease prevention) have also increased human life span. Genetic factors contribute to the variation of human life span by around 25%, which is believed to be more profound after 85 years of age. It is likely that multiple factors influence life span and we need answers to questions such as: 1) What does it take to reach 100?, 2) Do centenarians have better health during their lifespan compared with contemporaries who died at a younger age?, 3) Do centenarians have protective modifications of body composition, fat distribution and energy expenditure, maintain high physical and cognitive function, and sustained engagement in social and productive activities?, 4) Do centenarians have genes which contribute to longevity?, 5) Do centenarians benefit from epigenetic phenomena?, 6) Is it possible to influence the transgenerational epigenetic inheritance (epigenetic memory) which leads to longevity?, 7) Is the influence of nutrigenomics important for longevity?, 8) Do centenarians benefit more from drug treatment, particularly in primary prevention?, and, 9) Are there any potential goals for drug research? Many definitions of successful ageing have been proposed, but at present there is no consensus definition. Such definitions may need to differentiate between “Longevity Syndrome” and “Exceptional Longevity”.

Original languageEnglish (US)
Pages (from-to)662-673
Number of pages12
JournalCurrent Vascular Pharmacology
Volume12
Issue number5
StatePublished - 2014

Fingerprint

Epigenomics
Nutrigenomics
Body Fat Distribution
Primary Prevention
Body Composition
Vascular Diseases
Population Groups
Pharmaceutical Preparations
Cognition
Energy Metabolism
Life Style
Smoking
Exercise
Diet
Delivery of Health Care
Survival
Health
Research
Genes
Therapeutics

Keywords

  • Centenarians
  • Epigenetics
  • Exceptional longevity
  • Longevity syndrome

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Kolovou, G., Barzilai, N., Caruso, C., Sikora, E., Capri, M., Tzanetakou, I. P., ... Mikhailidis, D. P. (2014). The challenges in moving from ageing to successful longevity. Current Vascular Pharmacology, 12(5), 662-673.

The challenges in moving from ageing to successful longevity. / Kolovou, Genovefa; Barzilai, Nir; Caruso, Calogero; Sikora, Ewa; Capri, Miriam; Tzanetakou, Irene P.; Bilianou, Helen; Avery, Peter; Katsiki, Niki; Panotopoulos, George; Franceschi, Claudio; Benetos, Athanase; Mikhailidis, Dimitri P.

In: Current Vascular Pharmacology, Vol. 12, No. 5, 2014, p. 662-673.

Research output: Contribution to journalArticle

Kolovou, G, Barzilai, N, Caruso, C, Sikora, E, Capri, M, Tzanetakou, IP, Bilianou, H, Avery, P, Katsiki, N, Panotopoulos, G, Franceschi, C, Benetos, A & Mikhailidis, DP 2014, 'The challenges in moving from ageing to successful longevity', Current Vascular Pharmacology, vol. 12, no. 5, pp. 662-673.
Kolovou G, Barzilai N, Caruso C, Sikora E, Capri M, Tzanetakou IP et al. The challenges in moving from ageing to successful longevity. Current Vascular Pharmacology. 2014;12(5):662-673.
Kolovou, Genovefa ; Barzilai, Nir ; Caruso, Calogero ; Sikora, Ewa ; Capri, Miriam ; Tzanetakou, Irene P. ; Bilianou, Helen ; Avery, Peter ; Katsiki, Niki ; Panotopoulos, George ; Franceschi, Claudio ; Benetos, Athanase ; Mikhailidis, Dimitri P. / The challenges in moving from ageing to successful longevity. In: Current Vascular Pharmacology. 2014 ; Vol. 12, No. 5. pp. 662-673.
@article{84db4574537f49c3824af9acae27ed00,
title = "The challenges in moving from ageing to successful longevity",
abstract = "During the last decades survival has significantly improved and centenarians are becoming a fast-growing group of the population. Human life span is mainly dependent on environmental and genetic factors. Favourable modifications of lifestyle factors (e.g. physical activity, diet and not smoking) and healthcare (e.g. effective vascular disease prevention) have also increased human life span. Genetic factors contribute to the variation of human life span by around 25{\%}, which is believed to be more profound after 85 years of age. It is likely that multiple factors influence life span and we need answers to questions such as: 1) What does it take to reach 100?, 2) Do centenarians have better health during their lifespan compared with contemporaries who died at a younger age?, 3) Do centenarians have protective modifications of body composition, fat distribution and energy expenditure, maintain high physical and cognitive function, and sustained engagement in social and productive activities?, 4) Do centenarians have genes which contribute to longevity?, 5) Do centenarians benefit from epigenetic phenomena?, 6) Is it possible to influence the transgenerational epigenetic inheritance (epigenetic memory) which leads to longevity?, 7) Is the influence of nutrigenomics important for longevity?, 8) Do centenarians benefit more from drug treatment, particularly in primary prevention?, and, 9) Are there any potential goals for drug research? Many definitions of successful ageing have been proposed, but at present there is no consensus definition. Such definitions may need to differentiate between “Longevity Syndrome” and “Exceptional Longevity”.",
keywords = "Centenarians, Epigenetics, Exceptional longevity, Longevity syndrome",
author = "Genovefa Kolovou and Nir Barzilai and Calogero Caruso and Ewa Sikora and Miriam Capri and Tzanetakou, {Irene P.} and Helen Bilianou and Peter Avery and Niki Katsiki and George Panotopoulos and Claudio Franceschi and Athanase Benetos and Mikhailidis, {Dimitri P.}",
year = "2014",
language = "English (US)",
volume = "12",
pages = "662--673",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - The challenges in moving from ageing to successful longevity

AU - Kolovou, Genovefa

AU - Barzilai, Nir

AU - Caruso, Calogero

AU - Sikora, Ewa

AU - Capri, Miriam

AU - Tzanetakou, Irene P.

AU - Bilianou, Helen

AU - Avery, Peter

AU - Katsiki, Niki

AU - Panotopoulos, George

AU - Franceschi, Claudio

AU - Benetos, Athanase

AU - Mikhailidis, Dimitri P.

PY - 2014

Y1 - 2014

N2 - During the last decades survival has significantly improved and centenarians are becoming a fast-growing group of the population. Human life span is mainly dependent on environmental and genetic factors. Favourable modifications of lifestyle factors (e.g. physical activity, diet and not smoking) and healthcare (e.g. effective vascular disease prevention) have also increased human life span. Genetic factors contribute to the variation of human life span by around 25%, which is believed to be more profound after 85 years of age. It is likely that multiple factors influence life span and we need answers to questions such as: 1) What does it take to reach 100?, 2) Do centenarians have better health during their lifespan compared with contemporaries who died at a younger age?, 3) Do centenarians have protective modifications of body composition, fat distribution and energy expenditure, maintain high physical and cognitive function, and sustained engagement in social and productive activities?, 4) Do centenarians have genes which contribute to longevity?, 5) Do centenarians benefit from epigenetic phenomena?, 6) Is it possible to influence the transgenerational epigenetic inheritance (epigenetic memory) which leads to longevity?, 7) Is the influence of nutrigenomics important for longevity?, 8) Do centenarians benefit more from drug treatment, particularly in primary prevention?, and, 9) Are there any potential goals for drug research? Many definitions of successful ageing have been proposed, but at present there is no consensus definition. Such definitions may need to differentiate between “Longevity Syndrome” and “Exceptional Longevity”.

AB - During the last decades survival has significantly improved and centenarians are becoming a fast-growing group of the population. Human life span is mainly dependent on environmental and genetic factors. Favourable modifications of lifestyle factors (e.g. physical activity, diet and not smoking) and healthcare (e.g. effective vascular disease prevention) have also increased human life span. Genetic factors contribute to the variation of human life span by around 25%, which is believed to be more profound after 85 years of age. It is likely that multiple factors influence life span and we need answers to questions such as: 1) What does it take to reach 100?, 2) Do centenarians have better health during their lifespan compared with contemporaries who died at a younger age?, 3) Do centenarians have protective modifications of body composition, fat distribution and energy expenditure, maintain high physical and cognitive function, and sustained engagement in social and productive activities?, 4) Do centenarians have genes which contribute to longevity?, 5) Do centenarians benefit from epigenetic phenomena?, 6) Is it possible to influence the transgenerational epigenetic inheritance (epigenetic memory) which leads to longevity?, 7) Is the influence of nutrigenomics important for longevity?, 8) Do centenarians benefit more from drug treatment, particularly in primary prevention?, and, 9) Are there any potential goals for drug research? Many definitions of successful ageing have been proposed, but at present there is no consensus definition. Such definitions may need to differentiate between “Longevity Syndrome” and “Exceptional Longevity”.

KW - Centenarians

KW - Epigenetics

KW - Exceptional longevity

KW - Longevity syndrome

UR - http://www.scopus.com/inward/record.url?scp=84924171409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924171409&partnerID=8YFLogxK

M3 - Article

C2 - 24350930

AN - SCOPUS:84924171409

VL - 12

SP - 662

EP - 673

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 5

ER -